Global Industry Analysts, Inc., Oct 2011, Pages: 396
the condition of coronary restenosis. During the 2006-2007 period, the market for such stents (classified into Bare Metal Stents and DrugElutingStents (DES)), witnessed a period of decline as the DES segment
Jain PharmaBiotech, May 2012, Pages: 264
with the effects of circadian biological rhythms on drug actions.A full chapter is devoted to drug-elutingstents as treatment for restenosis following stenting of coronary arteries. Fifteen companies are involved
Axis Research Mind, Feb 2011, Pages: 363
OF RATE-RESPONSIVE PACEMAKERS WITH SEVERAL SENSORS - INDUSTRY OVERVIEW
TACHYCARDIA
CARDIOPULMONARY (CPB)
A DEVICE IDENTIFIES PATIENTS RISK
B. CORONARY STENS
CORONARY STENS – TYPES
A. DRUGELUTINGSTENTS
Global Industry Analysts, Inc., Sep 2011, Pages: 391
Angioplasty versus CABG - The Debate on the Most Effective
Procedure Continues 7
Drug-Eluting Balloons (DEBs) - A New Advancement
Global Industry Analysts, Inc., Jan 2011, Pages: 289
Stents Market (2005 & 2006):
Percentage Share Breakdown of Value Sales by Type- DrugEluting and Bare Metal Stents
By Region/Country
Table 6: World Market for CoronaryStents (2006): Percentage
Koncept Analytics, Aug 2010, Pages: 36
Population
- Advances in Technology
3.2 Market Developments
- Bioabsorbable Stents
- Next generation DrugElutingStents
4. CoronaryStent Market - Competitive Landscape
- Global Market
- US Market
5
Global Industry Analysts, Inc., June 2010, Pages: 492
Stents - The Best-Selling CoronaryStents II-5
Table 5: World Drug-ElutingStents Market (2007-2010):
Percentage Breakdown of Value Sales by Geographic Region -
US
Markets and Markets, March 2012, Pages: 471
of the market. In the global stents market, drug-elutingstents contributed the largest share with 76% of the total market, generating revenue of $8.9 billion in 2011 and is expected to reach $13.7 billion by 2016. The key
GlobalData, Dec 2011, Pages: 91
Experts and Key Opinion Leaders (KOLs)
The DrugEluting Balloons (DEBs) market is expected to grow at a Compound Annual Growth Rate (CAGR) of 8.1% to $127m by 2017. The Percutaneous Transluminal Coronary
Axis Research Mind, Feb 2011, Pages: 390
are the fastest growing regions while South Korea and Russia are just behind. Forecasts for drugelutingstent types indicate a close 65% while bare metal type accounts for nearly 25%. Predictions for BRICSS
GlobalData, April 2009, Pages: 56
number of indications such as in-stent restenosis, peripheral vascular disease and bifurcation lesions. The global drugeluting balloons (DEBs) market was valued at $60m in 2009 and is expected
Global Industry Analysts, Inc., Aug 2011, Pages: 200
. CORONARYSTENTS MARKET - A BRIEF OVERVIEW 34
Growth Revives as DrugElutingStents Bounce Back 34
DrugElutingStents Steal the Show 34
DrugElutingStent System - Safety Concerns 35
What's Next on Cards
Axis Research Mind, Feb 2011, Pages: 359
GRAFT SIZE FOR CARDIOPASS
EXTRA-AORTIC POST MARKET CLINICAL FOLLOW-UP (PMCF) ON PATIENTS
FDA APPROVAL CLEARS THE WAY FOR BOSTON SCIENTIFIC’S PROMUS EVEROLIMUS – ELUTINGCORONARYSTENT SYSTEM
ATS MEDICAL
Axis Research Mind, Feb 2011, Pages: 550
A. CARDIAC ABLATION
INTERVENTIONAL CARDIAC DEVICES
CORONARYSTENTING
A. DRUGELUTINGSTENTS (DES)
B. BARE METAL STENTS (BMS)
C. ABSORBABLE STENTS
BACKGROUND
PTCA BALLOON OR ANGIOPLASTY
WHAT IS PTCA
Axis Research Mind, Feb 2011, Pages: 396
BY THE
TANDEM HEART SYSTEM: PROMOSING DEVICE OF CARDIACASSIST, INC EXCEEDS 1300 PROCEDURES
ATRIUM MEDICAL’S “FIRST – IN-MAN” (FAM), DRUGELUTING CLINICAL TRIAL USING CINATRA™ VOCLOSPORIN COATED CORONARYSTENT
